Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009, 153(2):111-116 | DOI: 10.5507/bp.2009.018

β-GLUCAN-INDOMETHACIN COMBINATION PRODUCES NO LETHAL EFFECTS

Vaclav Vetvicka, Jana Vetvickova
University of Louisville, Department of Pathology, Louisville, KY

Background: The most important quality of β-glucans and the reason why so much attention has been devoted to them are their physiological effects. They are typical biological response modifiers with pronounced immunomodulating activity. However, some questions about possible side effects remain.

Aim: Several papers reported the lethal side effects of non-steroidal anti-inflammatory drugs in glucan-treated mice, probably due to the peritonitis by enteric bacteria. However, these results were never independently confirmed. The purpose of this study is to evaluate these claims using several different types of glucans.

Methods: Effects of combined treatment with four different types of glucans and indomethacin were measured by evaluation of phagocytosis of HEMA particles by peripheral blood leukocytes and production of IL-6 in mouse serum. In addition, the level of blood glucose, colon length and survival after 30 days of treatment was measured.

Results: Our finding showed that simultaneous treatment with glucan and indomethacin caused a small decrease of phagocytic activity and IL-2 production. Two other tested parameters-blood glucose levels and colon length-that had been found to be significantly affected by this treatment, were virtually unchanged. In the final, yet most important part of the study, we found absolutely no mortality, regardless of the type of glucan or the routes of glucan administration.

Conclusion: No adverse negative effects due to simultaneous treatment with glucan and non-steroidal anti-inflammatory drug dose was found, despite testing two different routes of glucan administration and four different types of glucan.

Keywords: Glucan, Indomethacin, Adverse effects, Phagocytosis, IL-6, Glucose

Received: November 30, 2008; Accepted: January 17, 2009; Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vetvicka, V., & Vetvickova, J. (2009). β-GLUCAN-INDOMETHACIN COMBINATION PRODUCES NO LETHAL EFFECTS. Biomedical papers153(2), 111-116. doi: 10.5507/bp.2009.018
Download citation

References

  1. Erdeve O, Sarici SU, Sari E, Gok F. Oral-ibuprofen-induced acute renal failure in a preterm infact. Pediatr. Nephrol. 2008;23:1566-1567. Go to original source... Go to PubMed...
  2. Sing S, Khajuria A, Taneja SC, Khajuria RK, Singh J, Jihri RK, Qazi GN. The gastric ulcer protective effect of boswellic acids, a leukotriene inhibitor from Boswellia serrata, in rats. Phytomedicine 2008; 15; 408-415. Go to original source... Go to PubMed...
  3. Novak M, Vetvicka V. Beta-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action, J. Immunotoxicol. 2008; 5: 47-57. Go to original source... Go to PubMed...
  4. Vetvicka V, Thornton BP, Ross GD. Soluble -glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.J. Clin. Invest. 1996; 98: 50-61. Go to original source... Go to PubMed...
  5. Czop JK, Austen KF. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte -glucan receptor. J. Immunol.1985; 135: 3388-3393. Go to original source... Go to PubMed...
  6. Janusz MJ, Austen KF, Czop JK. Isolation of a yeast heptaglucoside that inhibits monocyte phagocytosis of zymosan particles. J. Immunol. 1989; 142: 959-965. Go to original source... Go to PubMed...
  7. Jamois F, Ferrieres V, Guegan J-P, Yvin J-C, Plusquellec D, Vetvicka V. Glucan-like synthetic oligosaccharides - Iterative synthesis of linear oligo-{}-(1,3)-glucans and immunostimulatory effects. Glycobiology 2005; 15: 393-407. Go to original source... Go to PubMed...
  8. DiLuzio NR, Williams DL, McNamee RB, Edwards BF, Kitahame A. Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Internat, J. Cancer 1979; 24: 773-779. Go to original source... Go to PubMed...
  9. Zekovic DB, Kwiatkowski S, Vrvic MM, Jakovljevic D, Moran CA. Natural and modified (1-->3)-beta-D-glucans in health promotion and disease alleviation. Crit. Rev. Biotechnol. 2005; 25: 205-230. Go to original source... Go to PubMed...
  10. Rylander R, Thorn J, Attefors R. Airways inflammation among workers in a paper industry. Eur. Respir. J.1999; 13: 1151-1158. Go to original source... Go to PubMed...
  11. Sato M, Sano H. Direct binding to Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNFalpha secretion are down-regulated by lung collection surfactant protein. J. Immunol. 2003; 171: 417-425. Go to original source... Go to PubMed...
  12. Alwis KU, Mandryk J, Hocking AD. Exposure to biohazards in wood dust: bacteria, fungi, endotoxins, and (1-->3)-beta-Dglucans. Appl. Occupat. Environment. Hyg. 1999; 14: 598-608. Go to original source... Go to PubMed...
  13. Alwis KU, Milton DK. Recombinant factor C assay for measuring endotoxin in house dust: comparison with LAL, and (1 --> 3)-beta-D-glucans. Am. J. Ind. Med. 2006; 49: 296-300. Go to original source... Go to PubMed...
  14. Ljungman AG, Leanderson P, Tagesson C. Dglucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages. Environ. Toxicol. Pharmacol. 1998; 5: 273-281. Go to original source... Go to PubMed...
  15. Yoshiba S, Ohno N, Miura ST, Adachi Y, Yadomae T. Immunotoxicity of soluble -glucans induced by indomethacin treatment. FEMS Immunol. Med. Microbiol. 2001; 21: 171-179. Go to original source...
  16. Takahasmi H, Ohno N, Adachi Y, Yadomae T. Association of immunological disorders in lethal side effects of NSAIDs on -glucan-administered mice. FEMS Immunol. Med. Microbiol. 2001; 31: 1-14. Go to original source... Go to PubMed...
  17. Nameda S, Miura NN, Adachi Y, Ohno N. Antibiotics protect against septic shock in mice administered -glucan and indomethacin. Microbiol. Immunol. 2007; 51: 851-859. Go to original source... Go to PubMed...
  18. Nameda S, Miura NN, Adachi Y, Ohno N. Lincomycin protects mice from septic shock in -glucan-indomethacin model. Biol. Pharm. Bull. 2007; 30: 2312-2316. Go to original source... Go to PubMed...
  19. Vetvicka V, Fornusek L, Kopecek J, Kaminkova J, Kasparek L, Vranova M. Phagocytosis of human blood leukocytes: A simple micromethod. Immunol. Lett. 1982; 5: 97-100. Go to original source... Go to PubMed...
  20. Vetvicka V, Vetvickova J. An evaluation of the immunological activities if commercially available -1,3-glucans. J. Amer. Nutr. Assoc. 2007; 10: 25-31.
  21. Vetvicka V, Dvorak B, Vetvickova J, Richter J, Krizan J, Sima P, Yvin JC. Orally administered marine (1-->3)-beta-D-glucan Phycarine stimulates both humoral and cellular immunity. Int. J. Biol. Macromol. 2006; 40: 291-298. Go to original source... Go to PubMed...
  22. Patchen ML, MacVittie TJ. Use of glucan to enhance hemopoietic recovery after exposure to cobalt-60 irradiation, Adv. Exp. Med. Biol. 1982; 155: 267-272. Go to original source... Go to PubMed...
  23. Babicek K, Cechova I, Simon RR, Harwood M, Cox DJ. Toxicological assessment of a particulate yeast (1,3/1,6)--D-glucan in rats, Food Chem. Toxicol. 2007; 45: 1719-1730. Go to original source... Go to PubMed...
  24. Ohno N, Egawa Y, Hashimoto T, Adachi Y, Yadomae T. Effect of beta-glucans on the nitric oxide synthesis by peritoneal macrophage in mice. Biol. Pharm. Bull. 1996; 19: 608-612. Go to original source... Go to PubMed...
  25. Hashimoto T, Ohno N, Adachi Y, Yadomae T. Enhanced production of inducible nitric oxide synthase by -glucans in mice. FEMS Immunol. Med. Microbiol. 1997; 19: 134-135. Go to original source... Go to PubMed...
  26. Hibbs JB, Taintor RR, Vavrin Z. Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. Biochem. Biophys. Res. Commun. 1984; 123: 716-723. Go to original source... Go to PubMed...
  27. James S, Glaven J. Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J. Immunol. 1989; 143: 4208-4212. Go to original source... Go to PubMed...
  28. Billiar TR. Nitric oxide novel biology with clinical relevance. Ann. Surg. 1995; 221: 339-349. Go to original source... Go to PubMed...
  29. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am. J. Respir. Crit. Care Med. 2000; 161: 1781- 1785. Go to original source... Go to PubMed...
  30. Beijer L, Thorn J, Rylander R. Effects after inhalation of (1-->3)-beta-D-glucan and relation to mould exposure in the home. Mediators Inflam. 2002;11:149-153. Go to original source... Go to PubMed...
  31. Thippeswamy T, McKay JS, Quinn JP, Morris R. Nitric oxide, a biological double-faced janus - is this good or bad? Histol. Histopathol. 2006; 21: 445-448. Go to PubMed...